The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIV

Key Points

• The study aims to evaluate the plasma and intracellular levels of cabotegravir and rilpivirine after intramuscular administration in individuals with HIV.
• Measured plasma concentrations of cabotegravir and rilpivirine after intramuscular injection.
• Assessed intracellular levels of rilpivirine to understand potential impacts on treatment efficacy.
• Analyzed pharmacokinetic variables to examine variability in drug exposure.
• Plasma levels of cabotegravir and rilpivirine met expectations based on clinical trials.
• Intracellular levels of rilpivirine showed significant accumulation.
• Virological suppression was maintained despite observed pharmacokinetic variability.